Peptide Romania
performance

CJC-1295

Growth-hormone-releasing hormone analogue studied for GH/IGF-1 pulsatility.

Dovezi
Moderate
T½
~8 days (DAC)
Categorie
performance
Status
Investigational

Evaluarea dovezilor

Baza de dovezi

Moderate66%

Strong: Multiple studii umane controlate cu rezultate consistente și replicate de grupuri independente de cercetare.

Moderate: Studii umane sau animale cu semnale pozitive; există variabilitate metodologică sau date conflictuale limitate.

Emerging: Cercetare timpurie, predominant preclinică, cu rezultate promițătoare. Confirmarea umană este limitată.

Preliminary: Date foarte limitate, în principal rapoarte exploratorii sau studii singulare fără replicare independentă.

Farmacologie

Mecanism de acțiune

Growth-hormone-releasing hormone analogue studied for GH/IGF-1 pulsatility.

T½~8 days (DAC)
StatusInvestigational
Categorieperformance
DoveziModerate

Întrebări frecvente

Ce trebuie să știi

Growth-hormone-releasing hormone analogue studied for GH/IGF-1 pulsatility.
CJC-1295 has Moderate evidence. Human or animal studies show positive signals, but some methodological variation or conflicting data exists. Further large-scale trials are needed to confirm findings.
The half-life of CJC-1295 is ~8 days (DAC). This determines dosing frequency in research protocols — shorter half-lives require more frequent administration to maintain stable concentrations in study subjects.
CJC-1295 is currently classified as: Investigational. Regulatory status varies by jurisdiction — always consult local regulations and a qualified medical professional before any use outside an approved clinical context.
Growth-hormone-releasing hormone analogue studied for GH/IGF-1 pulsatility.
Înapoi la peptide